111In-LLP2A-DOTA polyethylene glycol-targeting α4β1 integrin: Comparative pharmacokinetics for imaging and therapy of lymphoid malignancies

Journal of Nuclear Medicine

Volumn 50, Issue 4, 2009, Pages 625-634

  Denardo, Sally J ^a   Liu, Ruiwu ^a   Albrecht, Huguette ^a   Natarajan, Arutselvan ^a   Sutcliffe, Julie L ^b,c   Anderson, Carolyn ^d   Peng, Li ^a   Ferdani, Riccardo ^d   Cherry, Simon R ^b,c   Lam, Kit S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4 '; 111in; 64Cu; PEGylation; PET

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; [[4 [[[(2 ETHYLPHENYL)AMINO]CARBONYL]AMINO]PHENYL]ACETYL] 6 [1 OXO 3 (3 PYRIDINYL 2 PROPENYL)] LYSYL 2 AMINOHEXANEDIOYL (1 AMINO 1 CYCLOHEXANE)CARBOXAMIDE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; [[4 [[[(2 ETHYLPHENYL)AMINO]CARBONYL]AMINO]PHENYL]ACETYL] 6 [1 OXO 3 (3 PYRIDINYL 2 PROPENYL)] LYSYL 2 AMINOHEXANEDIOYL (1 AMINO 1 CYCLOHEXANE)CARBOXAMIDE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID POLYETHYLENE GLYCOL IN 111; [[4 [[[(2 ETHYLPHENYL)AMINO]CARBONYL]AMINO]PHENYL]ACETYL] 6 [1 OXO 3 (3 PYRIDINYL 2 PROPENYL)] LYSYL 2 AMINOHEXANEDIOYL (1 AMINO 1 CYCLOHEXANE)CARBOXAMIDE 11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE CU 64; [[4 [[[(2 ETHYLPHENYL)AMINO]CARBONYL]AMINO]PHENYL]ACETYL] 6 [1 OXO 3 (3 PYRIDINYL 2 PROPENYL)] LYSYL 2 AMINOHEXANEDIOYL (1 AMINO 1 CYCLOHEXANE)CARBOXAMIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; DIAGNOSTIC AGENT; MACROGOL DERIVATIVE; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BONE MARROW; CANCER CELL CULTURE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG SPECIFICITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS; SPLEEN; TARGET ORGAN; WHOLE BODY AUTORADIOGRAPHY; XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; BURKITT LYMPHOMA; C57BL MOUSE; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BURKITT LYMPHOMA; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INTEGRIN ALPHA4BETA1; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MICE, NUDE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; POLYETHYLENE GLYCOLS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 63849329082     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.056903     Document Type: Article

References (34)

1. Dijkgraaf I, Boerman OC, Oyen WJG, Corstens FHM, Gotthardt M. Development and application of peptide-based radiopharmaceuticals. Anticancer Agents Med Chem. 2007;7:543-551.
2. Khan IU, Beck-Sickinger AG. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem. 2008; 8:186-199.
3. Okarvi SM. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev. 2008;34:13-26.
4. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med. 2007;48:615-622.
5. DeNardo GL, Hok S, Natarajan A, et al. Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. Int J Oncol. 2007;31:729-740.
6. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704-1713.
7. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697-715.
8. 3b for angiogenesis. Science. 1994;264:569-571.
9. 1). J Cell Biol. 1994;124:601-608.
10. 4- integrins in multiple sclerosis. Neurodegener Dis. 2008;5:16-22.
11. Fellermann K, Stange EF. How effective is natalizumab induction therapy in patients with Crohn's disease? Nat Clin Pract Gastroenterol Hepatol. 2008;5:78-79.
12. Holzmann B, Gosslar U, Bittner M. Alpha 4 integrins and tumor metastasis. Curr Top Microbiol Immunol. 1998;231:125-141.
13. Lam KS, Salmon SE, Hersh EM, Hruby V, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. Nature. 1991;354:82-84.
14. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against 04P1 integrin for in vivo tumor imaging. Nat Chem Biol. 2006;2:381-389.
15. Sprague JE, Peng Y, Sun X, et al. Preparation and biological evaluation of copper-64-labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res. 2004;10:8674-8682.
16. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin Cancer Res. 1997;3:71-79.
17. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci. 1949;51:660-666.
18. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
19. DeNardo GL, DeNardo SJ, Peterson JK, et al. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin Cancer Res. 2003;9:3865s-3872s.
20. Fand I, McNally WP. The technique of whole-body autoradiography. In: Johnson JE, ed. Current Trends in Morphological Techniques. Boca Raton, FL: CRC Press; 1981:1-28.
21. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem. 1988;263:15064-15070.
22. 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med. 2004;45:1776-1783.
23. Deckert PM, Jungbluth A, Montalto N, et al. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts. Int J Cancer. 2000;87:382-390.
24. 111In-DTPA- poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med. 2001; 42:1530-1537.
25. e6 polymer conjugate increases tumor targeting of photosensitizer. Cancer Res. 2001;61:7155-7162.
26. 3. Biotechniques. 2005;39(suppl):S6-S17.
27. 3 expression using
28. 18F-FPRGD4). J Nucl Med. 2007;48:1536-1544.
29. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 2002;17:641-646.
30. 3integrin-targeting radionuclide therapyandimagingwithmonomeric RGDpeptide. IntJCancer. 2008;123:709-715.
31. Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006;13:399-409.
32. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54:531-545.
33. Yang K, Basu A, Wang M, et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. 2003;16:761-770.
34. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. JMed Chem. 2004;47:1465-1474.